Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Growth hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    573 result(s) found for: Growth hormone. Displaying page 29 of 29.
    «« First « Previous 21  22  23  24  25  26  27  28  29 
    EudraCT Number: 2006-006550-96 Sponsor Protocol Number: TN-07 Start Date*: 2007-03-23
    Sponsor Name:NIDDK TYPE 1 DIABETES TRIALNET
    Full Title: Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus
    Medical condition: prevention of type 1 diabetes mellitus in subjects at risk for T1DM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) FI (Completed) DE (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002452-87 Sponsor Protocol Number: P-Monofer-IBD-03 Start Date*: 2017-09-11
    Sponsor Name:Pharmacosmos A/S
    Full Title: A randomized, double-blinded, comparative trial comparing the incidence of hypophosphatemia in relation to repeated treatment courses of iron isomaltoside and ferric carboxymaltose in subjects with...
    Medical condition: Iron deficiency anemia in subject with inflammatory bowel disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    20.0 10005329 - Blood and lymphatic system disorders 10079322 Anaemia of chronic inflammation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001896-19 Sponsor Protocol Number: P2-IMU-838-MS Start Date*: 2018-12-17
    Sponsor Name:Immunic AG
    Full Title: Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and t...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) DE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2019-001003-20 Sponsor Protocol Number: AFM13-202 Start Date*: 2019-09-16
    Sponsor Name:Affimed GmbH
    Full Title: A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides ...
    Medical condition: Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001518-39 Sponsor Protocol Number: K-877-303 Start Date*: 2017-01-16
    Sponsor Name:Kowa Research Institute, Inc.
    Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Pa...
    Medical condition: Severe hypertriglyceridemia [fasting TG levels >=500 mg/dL (5.65 mmol/L) and <2000 mg/dL (22.60 mmol/L) and mild or moderate renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-003511-37 Sponsor Protocol Number: K-877-301 Start Date*: 2017-01-16
    Sponsor Name:Kowa Research Institute, Inc.
    Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double­Blind, 12-Week Study With a 40-Week, Active-Controlled, Double­Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult ...
    Medical condition: severe hypertriglyceridemia [fasting TG levels >=500 mg/dL (5.65 mmol/L) and <2000 mg/dL (22.60 mmol/L)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002676-27 Sponsor Protocol Number: MedOPP096-MO39229 Start Date*: 2017-05-25
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study
    Medical condition: HER2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Completed) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000084-16 Sponsor Protocol Number: NC-6004-004A Start Date*: 2016-11-24
    Sponsor Name:NanoCarrier Co, Ltd
    Full Title: A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non-Small Cell Lung, Biliary Tract, and Blad...
    Medical condition: Advanced solid tumors and first-line metastatic squamous NSCLC; first-line metastatic or locally advanced cholangiocarcinoma, gallbladder cancer, or ampullary cancer (biliary tract cancer); and fir...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017614 Gallbladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000558-37 Sponsor Protocol Number: ARQ092-103 Start Date*: 2017-02-22
    Sponsor Name:ArQule, Inc.
    Full Title: A Phase 1/2 Study of ARQ 092 in Patients with Overgrowth Diseases and Vascular Anomalies with Genetic Alterations of the PI3K/AKT Pathway
    Medical condition: subjects (at least 6 years) suffering from diseases overgrowth and vascular anomalies with genetic alterations of the PI3K / AKT pathway.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) ES (Temporarily Halted) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003609-32 Sponsor Protocol Number: BGBC008/MK-3475PN-531 Start Date*: 2018-08-24
    Sponsor Name:BerGenBio ASA
    Full Title: A Phase II Multi-Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung.
    Medical condition: Previously Treated Advanced Adenocarcinoma of the Lung
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001160 Adenocarcinoma lung LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-003899-31 Sponsor Protocol Number: DBC-AMD-001-D Start Date*: 2018-05-28
    Sponsor Name:DOBECURE, S.L
    Full Title: International, multicenter, randomised, blind, sham-controlled, 2x2 cross over phase III clinical trial to assess the efficacy and security of an intravitreal injection of Etamsylate in the improv...
    Medical condition: Aged related macula degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000314-38 Sponsor Protocol Number: 1206-HNCG Start Date*: 2014-07-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expre...
    Medical condition: Salivary gland cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) HU (Completed) AT (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003447-11 Sponsor Protocol Number: C-145-04 Start Date*: 2017-10-27
    Sponsor Name:Iovance Biotherapeutics, Inc.
    Full Title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
    Medical condition: Recurrent, metastatic, or persistent Cervical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Prematurely Ended) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 21  22  23  24  25  26  27  28  29 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 09:33:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA